*North Carolina Editor Tipoffs Newsletter for Monday March 17, 2025 ( 4 items ) |
EPA Releases Public Communication From GreenLatinos
WASHINGTON, March 16 -- The U.S. Environmental Protection Agency has released the following public communication dated March 3, 2025, from GreenLatinos:
* * *
To: Marcy Card
Existing Chemicals Risk Management Division
Office of Pollution Prevention and Toxics
Environmental Protection Agency
1200 Pennsylvania Ave. NW Washington, DC 20460-000195812
Re: Comments on the Draft Scope of the Risk Evaluation Under the Toxic Substances Control Act (TSCA) for Vinyl Chloride; Docket Number: EPA-HQ-O
more
IRS Releases Public Communication From Forvis Mazars LLP
WASHINGTON, March 16 -- The U.S. Department of the Treasury Internal Revenue Service has released the following public communication dated Feb. 27, 2025, from Forvis Mazars LLP, Charlotte, North Carolina:
* * *
To: Internal Revenue Service
CC:PA:01:PR (REG-105479-18)
Room 5203
P.O. Box 7604, Ben Franklin Station
Washington, DC 20044
Re: Previously Taxed Earnings and Profits and Related Basis Adjustments
* * *
Dear Sir or Madam:
On December 2, 2024, the Department of the Treasury (Treas
more
Markey, Whitehouse Lead EPW Democrats in Demanding Zeldin Halt Political Witch Hunt Against Money-Saving Clean Energy Investments
WASHINGTON, March 14 -- Sen. Edward J. Markey, D-Massachusetts, issued the following news release:
* * *
Markey, Whitehouse Lead EPW Democrats in Demanding Zeldin Halt Political Witch Hunt Against Money-Saving Clean Energy Investments
Administrator Zeldin is manipulating facts as a pretext to terminate a congressionally appropriated and legally obligated program that would lower household energy costs, spur economic development, and reduce pollution
Washington, (March 14, 2025) - Today, Sen
more
Sterling Pharma USA Seeks DEA Approval for Bulk Manufacturing of Schedule I Substances
WASHINGTON, March 15 (TNSFR) -- Sterling Pharma USA LLC, based in Cary, North Carolina, has applied to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of several Schedule I controlled substances. The company is seeking approval to produce tetrahydrocannabinols, psilocybin, dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, and psilocyn.
According to the DEA filing, Sterling Pharma USA intends to manufacture these substances to support internal research effor
more
|
Sign up to Receive this newsletter every day via email.